Browsing by Author "University of Colorado"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Effects of pharmacist interventions on heart failure outcomes: A systematic review and meta-analysis
    (2021-07-01) Poukwan Arunmanakul; Kirati Kengkla; Thanaputt Chaiyasothi; Arintaya Phrommintikul; Chidchanok Ruengorn; Unchalee Permsuwan; Ammarin Thakkinstian; Robert L. Page; Mark A. Munger; Surakit Nathisuwan; Nathorn Chaiyakunapruk; University of Phayao; University of Utah School of Medicine; Faculty of Medicine Ramathibodi Hospital, Mahidol University; Mahidol University; University of Utah Health; Chiang Mai University; Srinakharinwirot University; University of Colorado
    Heart failure (HF) patients tend to have multiple comorbidities resulting in complex therapy regimens and medication adherence issues. Nevertheless, the evidence of pharmacists' contributions to improving clinical outcomes in HF is limited. To assess the impact of pharmacist intervention on all-cause hospitalization, mortality, and quality of life (QoL) in HF) patients. A systematic search of PubMed, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and CINAHL was performed up to April 30, 2020. Randomized controlled trials (RCTs) evaluating pharmacist interventions compared with usual care in adult HF patients were selected. Data were extracted independently by two authors. Random effects meta-analysis models were used to pool treatment effects and confidence intervals (CIs). Twenty-nine trials identified 6965 predominantly HF with reduced ejection fraction (HFrEF) patients. The average age was 72.0 years (interquartile range [IQR] 66.0-76.0) and 48% were men (IQR 40.0%-68.0%). The majority were New York Heart Association (NYHA) Functional class (FC) II-III with median left ventricular ejection fraction (LVEF) of 38.5% (IQR 34.5%-49.5%). Pharmacist interventions were associated with a significant reduction of all-cause mortality (risk ratio [RR] 0.72; 95% CI 0.58-0.89; P = 0.003) and all-cause hospitalizations (RR 0.87; 95% CI 0.77-0.99; P = 0.041). A significant increase in the 36-item Short form Health survey (SF-36) on role physical (Mean deviation [MD], 8.5; 95% CI, 1.00 to 16.01, P = 0.026) and mental health (MD, 7.49; 95% CI, 3.88 to 11.10, P < 0.001) were observed. In addition, a significant improvement in Minnesota Living with Heart Failure Questionnaire score was observed (MD -3.55; 95% CI -6.28 to −0.82; P = 0.01). Pharmacist interventions in patients with HF significantly reduced all-cause mortality and hospitalizations and improved QoL. Integration of a pharmacist into a HF care team or care pathway should be strongly considered as an important element of a multidisciplinary team.
  • No Thumbnail Available
    PublicationMetadata only
    International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
    (2020-01-01) Sarah K. Wise; Sandra Y. Lin; Elina Toskala; Richard R. Orlandi; Cezmi A. Akdis; Jeremiah A. Alt; Antoine Azar; Fuad M. Baroody; Claus Bachert; G. Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S. Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M. DelGaudio; Charles S. Ebert; Jean Anderson Eloy; Carrie E. Flanagan; Wytske J. Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G. Hamilton; Hans Jürgen Hoffman; Jens M. Hohlfeld; Steven M. Houser; Peter H. Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N. Khalid; Maritta Kilpeläinen; Todd T. Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M. Laury; Stella E. Lee; Joshua M. Levy; Amber U. Luong; Bradley F. Marple; Edward D. McCoul; K. Christopher McMains; Erik Melén; James W. Mims; Gianna Moscato; Joaquim Mullol; Harold S. Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P. Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J. Schlosser; Russell A. Settipane; Hemant P. Sharma; Aziz Sheikh; Timothy L. Smith; Pongsakorn Tantilipikorn; Jody R. Tversky; Maria C. Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek; University of Texas Rio Grande Valley; Ospedale Policlinico San Martino; National Jewish Health; Universiteit Gent; Wake Forest University; University of California, San Diego; Temple University; Aarhus Universitet; The University of Chicago; Eskişehir Osmangazi Üniversitesi; University of Texas Health Science Center at Houston; The University of Edinburgh; Turun Yliopistollinen Keskussairaala; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM; The University of Utah; School of Medicine and Health Sciences; Medical University of South Carolina; Loyola University New Orleans; Boston University; Nippon Medical School; Ochsner Health System; The University of North Carolina System; National University of Singapore; Universität Heidelberg; Oregon Health & Science University; University of Pittsburgh; Università degli Studi di Pavia; Imperial College London; Hospital Regional Universitario Carlos Haya; Mahidol University; Stanford University; Karolinska Institutet; Swiss Institute of Allergy and Asthma Research; The Warren Alpert Medical School; Weill Cornell Medicine; Uniformed Services University of the Health Sciences; Johns Hopkins University; Rutgers New Jersey Medical School; Harvard Medical School; Universiteit van Amsterdam; University of Calgary; Universitat de Barcelona; Emory University; Case Western Reserve University; Humanitas University; San Antonio Military Medical Center; University of Missouri; University of Michigan; ASST Pini/CTO; Hospital Universitario Fundacion Jiminez Diaz; University of Texas Southwestern; Otorhinolaryngology; University of Colorado; Hospital Médica Sur; Otolaryngology; Allergy/Immunology
  • No Thumbnail Available
    PublicationMetadata only
    Pharmacokinetics and safety of maraviroc in neonates
    (2021-03-01) Julia C. Rosebush; Brookie M. Best; Ellen G. Chadwick; Kevin Butler; John Moye; Elizabeth Smith; Sarah Bradford; Christina A. Reding; Sisinyana R. Mathiba; Sherika Hanley; Mariam Aziz; James Homans; Edward P. Acosta; William Murtaugh; Manoli Vourvahis; Lynn McFadyen; Katy Hayward; Mark Mirochnick; Pearl Samson; Ntatule Hilda Ndiweni; Zaakirah Essack; Mandisa Nyati; Lorna Pillay; Rosemary Gazu; Natasha Pillay; Damien Sookoo; Kulkanya Chokephaibulkit; Supattra Rungmaitree; Keswadee Lapphra; Orasri Wittawatmongkol; Isaac Tsikhutsu; Edner Openda; Priscillah Bii; David Wekulo; Ellen Chadwick; Jessica D’Angelo; Margaret Ann Sanders; Alice Stek; Mikhaela Cielo; La Shonda Spencer; Yvonne Morales; Christiana Smith-Anderson; Kacey Navarro; Carrie Glenny; Elizabeth McFarland; R. N. Maureen McNichols; Julie Schmidt; Helen Cejtin; Ixchell Ortiz-Estes; Katherine Knapp; Nehali Patel; Patricia M. Flynn; Jill Utech; Kathleen George; Shane Reynolds; Terence Fenton; Michelle Hsu; Jamie Branco-Ricard; Victoria Wong; Barbara Heckman; Kyle Whitson; Shawn Ward; Navdeep K. Thoofer; Siriraj Hospital; FHI 360; ViiV Healthcare; Pfizer Limited, UK; Frontier Science & Technology Research Foundation, Inc.; Kenya Medical Research Institute; Harvard T.H. Chan School of Public Health; University of California, San Diego; University of Southern California; The University of Chicago; The University of Alabama at Birmingham; Children's Hospital Los Angeles; St. Jude Children's Research Hospital; Boston University; Rush University Medical Center; National Institute of Allergy and Infectious Diseases (NIAID); Ann & Robert H. Lurie Children's Hospital of Chicago; University of the Witwatersrand, Johannesburg; University of KwaZulu-Natal; National Institutes of Health (NIH); Rush University; IMPAACT Statistical and Data Analysis Center; IMPAACT Data Management Center; IMPAACT Laboratory Center; CAPRISA Umlazi Clinical Research Site; IMPAACT Operations Center; University of Colorado; Ann and Robert H. Lurie Children's Hospital of Chicago; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Pfizer Global Research and Development
    Objective: The aim of this study was to evaluate safety and pharmacokinetics of maraviroc administered with standard antiretroviral prophylaxis to HIV-1 exposed infants and to determine the appropriate dose of maraviroc during the first 6 weeks of life. Design: A phase I, multicentre, open-label study enrolling two sequential cohorts. Methods: IMPAACT 2007 participants enrolled by day 3 of life and were stratified by exposure to maternal efavirenz. Cohort 1 participants received two single 8 mg/kg maraviroc doses 1 week apart with pharmacokinetic sampling after each dose. Cohort 2 participants received 8 mg/kg maraviroc twice daily through 6 weeks of life with pharmacokinetic sampling at weeks 1 and 4. Maraviroc exposure target was Cavg at least 75 ng/ml. Laboratory and clinical evaluations assessed safety. Results: Fifteen Cohort 1 and 32 Cohort 2 HIV-exposed neonates were enrolled (median gestational age 39 weeks, 51% male). All 13 evaluable Cohort 1 infants met the pharmacokinetic target. Median exposure for the 25 evaluable Cohort 2 infants met the pharmacokinetic target but variability was high, with 17–33% of infants below target at Weeks 1 and 4. Pharmacokinetic target achievement was similar between efavirenz exposure strata. No Grade 3þ toxicities, early study or treatment discontinuations due to maraviroc occurred. Conclusion: Median maraviroc exposure met the Cavg target in neonates receiving 8 mg/kg twice daily, although exposures were variable. Maternal efavirenz use did not impact maraviroc exposure and no discontinuations were due to maraviroc toxicity/ intolerance. No infants acquired HIV-1 infection during follow-up. Maraviroc 8 mg/kg twice daily appears well tolerated during the first 6 weeks of life.